We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global POC Urinalysis Market Driven by Nephropathic Disorders and UTIs

By LabMedica International staff writers
Posted on 18 Dec 2018
The global point of care (POC) urinalysis market is projected to grow at a CAGR of more than 3% over the 2018-2022 period, driven mainly by the rising prevalence of nephropathic disorders and urinary tract infections (UTIs) which is generating higher demand for various types of urine tests. More...
These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

Lifestyle diseases such as obesity, diabetes, and hypertension adversely impact the excretion system, including the lungs, kidneys, skin, bladder, and urinary tract. This impacts the appearance, concentration, and content of urine, resulting in various nephropathic disorders. Globally, UTI is the most common non-intestinal infection, whereas chronic kidney disease (CKD) is a major public health problem. The increase in the incidence of UTIs and nephropathic disorders is driving the growing demand for diagnostic systems, especially POC, as it is the fastest growing segment of the diagnostic systems market. A urinary screening program is recommended as a fundamental element for reducing the incidence of CKDs and UTIs, which is expected to fuel the demand for urinalysis tests and boost the growth of the POC urinalysis market.

The global POC urinalysis market is expected to become slightly fragmented during the forecast period due to the presence of several POC urinalysis device manufacturers who are offering POC devices, such as urinalysis test systems and urinalysis test consumables. The growth of the global POC urinalysis market is likely to be further supported by emerging technologies in POC testing. A number of POC urinalysis device manufacturers are focusing on developing new technologies, such as lateral flow immunoassay (LFIA) platforms, reflectometry, and automated urine microscopy analyzers.

Various companies are developing and distributing products in partnership, which helps them to cover a larger geographical area and earn higher return on earnings (ROI) as the products are co-developed and marketed. Such combined products provide better analysis by continuous load-and-go processing with no centrifugation, reduced offline dilutions, and fewer manual steps. With several established POC urinalysis device manufacturers battling for market share, the players will need to differentiate themselves in order to gain significant traction over their peers.

Geographically, in 2017, the largest share in the global POC urinalysis market was held by the Americas at 45%, followed by EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific). The Americas is expected to continue dominating the global POC urinalysis market during the forecast period with a share of almost 43%, led by the high prevalence of CKD and UTIs in the region, as well as increasing health consciousness of lifestyle diseases among its population. On the other hand, the POC urinalysis market in APAC is projected to register the fastest growth among the three regions.

Related Links:
Technavio Research


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.